Xilio Therapeutics, Inc. (XLO)
9.05
+0.04
(+0.44%)
USD |
NASDAQ |
Oct 09, 16:00
9.08
+0.03
(+0.33%)
After-Hours: 20:00
Xilio Therapeutics Enterprise Value : -70.19M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | -70.19M |
| October 08, 2026 | -70.45M |
| October 07, 2026 | -70.45M |
| October 06, 2026 | -70.52M |
| October 05, 2026 | -69.79M |
| October 02, 2026 | -70.45M |
| October 01, 2026 | -71.11M |
| September 30, 2026 | -70.19M |
| September 29, 2026 | -70.93M |
| September 28, 2026 | -70.19M |
| September 25, 2026 | -70.25M |
| September 24, 2026 | -70.52M |
| September 23, 2026 | -70.91M |
| September 22, 2026 | -70.25M |
| September 21, 2026 | -70.38M |
| September 18, 2026 | -69.66M |
| September 17, 2026 | -70.25M |
| September 16, 2026 | -70.65M |
| September 15, 2026 | -70.32M |
| September 14, 2026 | -70.98M |
| September 11, 2026 | -70.98M |
| September 10, 2026 | -70.98M |
| September 09, 2026 | -70.71M |
| September 08, 2026 | -71.11M |
| September 04, 2026 | -70.52M |
| Date | Value |
|---|---|
| September 03, 2026 | -70.38M |
| September 02, 2026 | -71.57M |
| September 01, 2026 | -71.31M |
| August 31, 2026 | -70.85M |
| August 28, 2026 | -70.52M |
| August 27, 2026 | -70.45M |
| August 26, 2026 | -70.19M |
| August 25, 2026 | -69.99M |
| August 24, 2026 | -69.27M |
| August 21, 2026 | -69.00M |
| August 20, 2026 | -69.00M |
| August 19, 2026 | -67.82M |
| August 18, 2026 | -67.23M |
| August 17, 2026 | -67.29M |
| August 14, 2026 | -69.40M |
| August 13, 2026 | -70.45M |
| August 12, 2026 | -70.19M |
| August 11, 2026 | -69.33M |
| August 10, 2026 | -69.20M |
| August 07, 2026 | -69.40M |
| August 06, 2026 | -68.74M |
| August 05, 2026 | -69.79M |
| August 04, 2026 | -69.92M |
| August 03, 2026 | -70.19M |
| July 31, 2026 | -69.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cue Biopharma, Inc. | 136.06M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.373M |
| Revenue (Quarterly) | 18.69M |
| Total Expenses (Quarterly) | 25.06M |
| EPS Diluted (Quarterly) | -0.3284 |
| Gross Profit Margin (Quarterly) | 98.23% |
| Profit Margin (Quarterly) | -34.09% |
| Earnings Yield | -18.63% |
| Normalized Earnings Yield | -19.89 |